Welcome to our dedicated page for Altimmune SEC filings (Ticker: ALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Altimmune, Inc. (ALT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. Altimmune’s common stock, par value $0.0001 per share, is registered on The Nasdaq Global Market under the symbol ALT, and its Exchange Act and Securities Act filings offer detailed insight into its clinical, financial and corporate activities.
For a late clinical-stage company focused on peptide-based therapeutics for liver, metabolic and cardiometabolic diseases, periodic reports and current reports are particularly important. Forms such as the annual report on Form 10-K and quarterly reports on Form 10-Q (when available) describe Altimmune’s business, risk factors, clinical programs and financial condition. Current reports on Form 8-K document material events, including clinical trial results for pemvidutide, Fast Track and Breakthrough Therapy designations, equity distribution agreements for at-the-market offerings, amendments to loan facilities, executive transitions and annual meeting outcomes.
Altimmune’s proxy materials, such as the definitive proxy statement on Form DEF 14A, outline governance matters, board composition, executive compensation and items submitted to stockholders at the annual meeting. These filings help investors understand how the company is overseen and how leadership is incentivized as it advances pemvidutide through Phase 2 and prepares for planned Phase 3 development in MASH.
On Stock Titan, Altimmune filings are updated in near real time as new documents are posted to EDGAR. AI-powered tools summarize lengthy filings, highlight key terms in agreements such as loan amendments or equity distribution arrangements, and make it easier to locate information on topics like clinical milestones, financing capacity or voting results. Users can also review disclosures related to capital structure, including at-the-market programs and term loan facilities, to see how Altimmune funds its liver and cardiometabolic disease pipeline.
Altimmune reported strong clinical topline results from its IMPACT Phase 2b MASH trial, where weekly pemvidutide produced MASH resolution rates of 59.1% (1.2 mg) and 52.1% (1.8 mg) versus 19.1% for placebo (p<0.0001 for both doses). Fibrosis improvement by conventional ITT analysis was not statistically different, but an AI-based analysis showed a larger fibrosis reduction signal (30.6% of subjects on 1.8 mg achieved ≥60% fibrosis reduction versus 8.2% on placebo, p<0.001). Pemvidutide also drove mean weight loss of 5.0% and 6.2% at 1.2 mg and 1.8 mg versus 1.0% for placebo, and safety/tolerability appeared favorable with low discontinuation rates.
On the balance sheet, cash and equivalents were $183.1M at June 30, 2025, the company drew $15.0M of a $100M term loan facility (effective interest rate 14.4%), and generated net proceeds of $72.6M from at-the-market equity offerings in the period plus an additional $12.8M raised in July. The company recorded a six-month net loss of $41.7M and has an accumulated deficit of $603.1M. A class action alleging securities law violations was filed on August 5, 2025.
Altimmune, Inc. filed a current report to furnish a press release announcing its financial results for the second quarter ended June 30, 2025. The press release, dated August 12, 2025, is included as Exhibit 99.1 and is provided for informational purposes rather than being formally filed under securities laws.
Altimmune (Nasdaq: ALT) filed an 8-K reporting positive topline data from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).
- MASH resolution without fibrosis worsening reached 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% placebo (p<0.0001).
- Histologic fibrosis improvement (31.8%/34.5% vs 25.9% placebo) was not significant, but AI analysis showed ≥60% fibrosis reduction in 30.6% at 1.8 mg vs 8.2% placebo (p<0.001).
- Mean weight loss 5.0%/6.2% vs 1.0% placebo (p<0.001); liver fat fell 58.0%/62.8% vs 16.2%.
- Safety: 0–1.2% AE-related discontinuations; no drug-related SAEs.
Slides (Ex 99.2) accompany a call on 26 Jun 2025. Forward-looking statements cite regulatory, trial and funding risks.